Evotec SE (NASDAQ:EVO - Get Free Report) saw strong trading volume on Friday . 100,459 shares traded hands during trading, a decline of 5% from the previous session's volume of 106,043 shares.The stock last traded at $3.89 and had previously closed at $3.87.
A number of analysts recently weighed in on EVO shares. Jefferies Financial Group lowered shares of Evotec from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $8.70 to $3.80 in a research note on Monday, October 7th. Deutsche Bank Aktiengesellschaft downgraded shares of Evotec from a "hold" rating to a "sell" rating in a research note on Thursday, August 8th. Morgan Stanley downgraded shares of Evotec from an "overweight" rating to an "equal weight" rating and reduced their price objective for the stock from $15.00 to $6.00 in a research note on Monday, July 29th. Finally, HC Wainwright dropped their target price on Evotec from $11.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $5.93.
View Our Latest Analysis on Evotec
The stock has a 50-day moving average of $3.43 and a 200 day moving average of $4.36. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.83 and a quick ratio of 1.73.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVO. Cetera Advisors LLC purchased a new stake in Evotec in the 1st quarter worth approximately $188,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Evotec during the second quarter worth $87,000. DCF Advisers LLC grew its position in Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock valued at $552,000 after buying an additional 67,156 shares during the period. Novo Holdings A S purchased a new position in Evotec in the second quarter valued at $71,183,000. Finally, Mediolanum International Funds Ltd purchased a new position in Evotec in the third quarter valued at $512,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.